Table 3.

The effect of different factors on linear growth in children with idiopathic short stature (ISS) on treatment with rhGH

	Ht-SDS MP-Ht-SDS before GH Therapy	Ht-SDS - MP-HT-SDS after GH therapy	Ht-SDS gain after GH therapy
Ht -SDS <-2.5	-1.20	-0.20*#	0.98#
Ht-SDS >-2.5>-2	-0.93	-0.32*	0.60
More than 1SD below their MP-Ht-SDS before GH therapy	-1.5	-0.57*#	0.88#
Less than 1SD below their MP-Ht-SDS before GH therapy	-0.71	-0.1*	0.62
IGF-I increment >150%	-1.2	-0.4*	0.7
IGF-I increment <150%	-1.1	-0.25*	0.83
GH response >15 ng/dl	-1.13	-0.29*	0.8
GH response <15 ng/dl	-1.07	-0.37*	0.69
Remained as prepubertal during therapy	-1.34	-0.27*	0.71
Progression to Tanner 3 during therapy	-1.36	-0.37*	0.78
Age <9 years at the start of GH	-1.2	-0.1*#	1.1#
Age >9 years at the start of GH	-1.04	-0.45*	0.58

Legend *=p<0.05 before vs after therapy, #= p<0.05 comparing different groups